 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | metolazone IV / Academic Pharma
Retrospective data, Journal: Meta-Analysis Comparing Metolazone Versus Intravenous Chlorothiazide in Patients With Acute Decompensated Heart Failure. (Pubmed Central) - Mar 16, 2025
No abstract available
- acetazolamide / Generic mfg.
ACETAZOLAMIDE VERSUS THIAZIDES WITH LOOP DIURETICS IN ACUTE DECOMPENSATED HEART FAILURE - Allyson Chan (Board no. 142; South Hall) - Jan 27, 2025 - Abstract #ACC2025ACC_1796;
There is no significant difference in average daily net urine output or safety outcomes among patients with ADHF on thiazide and loop, acetazolamide and loop, or all three classes of diuretics, even after adjusting for potential confounders. Further studies are warranted to determine optimal timing and doses of each diuretic when used in combination.
- metolazone IV / Academic Pharma
Needing bail-out therapy to stabilise outpatient worsening heart failure highlights a high-risk cohort for recurrent instability (ePosters screen 8) - Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_588;
Those stabilised initially with aggressive outpatient diuresis had a particularly high risk of future deterioration with 46% experiencing recurrent outpatient WHF or HFH at 3 months. This suggests that close, structured clinical follow-up, including home telemonitoring, akin to that after HFH, could be beneficial in this cohort
- metolazone IV / Academic Pharma
THE EFFECT OF ELECTRONIC HEALTH RECORD CHOICE ARCHITECTURE ON DIURETIC AUGMENTATION CHOICE (Moderated Poster Theater 02) - Jan 26, 2024 - Abstract #ACC2024ACC_3937;
Background: Metolazone and intravenous (IV) chlorothiazide are commonly used for sequential nephron blockade in acute decompensated heart failure (ADHF) with similar efficacy and safety, however, IV chlorothiazide is significantly more expensive... In patients treated for ADHF, modulating the EHR choice architecture through a simple alert significantly reduced chlorothiazide dispenses, providing an avenue for cost reduction in admissions for ADHF.
- metolazone IV / Academic Pharma
Outpatient worsening heart failure managed in dedicated heart failure unit --workload and outcomes (ePosters Station 3) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_909;
This ongoing prospective analysis of WHF managed in an outpatient heart failure unit underlines that while the majority can be settled without the need for hospitalisation, the workload is significant and resource intensive often requiring a combination of different diuretic strategies. Only the minority return to baseline diuretic dose prior to the WHF episode indicating a concerning prognostic trend even in the group successfully managed in the community
- metolazone IV / Academic Pharma
Persistently high early morbidity following outpatient stabilisation of worsening heart failure: 1- and 3-month outcomes of worsening heart failure managed in an outpatient setting (Moderated ePosters 1) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_621;
These data support the emerging awareness of the prognostic significance of outpatient WHF and the need for more vigilant follow-up in the early period after stabilisation akin to that post-HFH. They also suggest that, while patients may be defined clinically as stabilised, many may have residual subclinical congestion increasing risk of early future clinical deterioration.
- | metolazone IV / Academic Pharma
Retrospective data, Journal: Metolazone versus intravenous chlorothiazide for decompensated heart failure sequential nephron blockade: A retrospective cohort study. (Pubmed Central) - Aug 18, 2022
Chlorothiazide was not superior to metolazone in changing the net 24-hour UOP of patients with ADHF and loop resistance. Preferential metolazone use in SNB is a potential cost-saving measure.
- | metolazone IV / Academic Pharma
Journal: Formulation, Characterization, and the Diuretic Effects of a New Intravenous Metolazone Emulsion. (Pubmed Central) - Jul 8, 2022
Preferential metolazone use in SNB is a potential cost-saving measure. This metolazone emulsion was capable of increasing urine volume output and demonstrated both natriuretic and kaliuretic properties.
- metolazone IV / Academic Pharma
[VIRTUAL] Safety and efficacy of oral metolazone versus intravenous chlorothiazide in acute decompensated heart failure () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2367;
Safety endpoints included electrolyte abnormalities, worsening renal function, and hypotension. Secondary objectives included change in net urine output at 12 and 24 hours, change in standing weight by 48 hours, readmission rate, and need for any form of renal replacement therapy.
- metolazone IV / Academic Pharma
[VIRTUAL] Evaluation of intravenous chlorothiazide use in the setting of acute decompensated heart failure. () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1374;
Metolazone has been shown to be non-inferior to chlorothiazide IV in increasing urine output in patients with ADHF. Given these results, we believe there is opportunity to increase utilization of metolazone, as well as potential to reduce institutional drug costs due to the significant cost difference between IV chlorothiazide and metolazone.
- | metolazone IV / Academic Pharma
Journal: Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction. (Pubmed Central) - Nov 27, 2019
Both MTZ and CTZ similarly increased UOP when utilized as an adjunct to IV LD. These results suggest that while thiazide agents can substantially increase UOP in ADHF patients with HFrEF, MTZ and CTZ have comparable effects.